252 related articles for article (PubMed ID: 12909720)
1. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.
Resnick MA; Inga A
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9934-9. PubMed ID: 12909720
[TBL] [Abstract][Full Text] [Related]
2. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
3. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
Inga A; Monti P; Fronza G; Darden T; Resnick MA
Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
5. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
6. Reporter gene regulation in Saccharomyces cerevisiae by the human p53 tumor suppressor protein.
Bitter GA; Schaeffer TN; Ellison AR
J Mol Microbiol Biotechnol; 2002 Nov; 4(6):539-50. PubMed ID: 12432954
[TBL] [Abstract][Full Text] [Related]
7. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.
Inga A; Nahari D; Velasco-Miguel S; Friedberg EC; Resnick MA
Oncogene; 2002 Aug; 21(37):5704-15. PubMed ID: 12173040
[TBL] [Abstract][Full Text] [Related]
8. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation.
Tomso DJ; Inga A; Menendez D; Pittman GS; Campbell MR; Storici F; Bell DA; Resnick MA
Proc Natl Acad Sci U S A; 2005 May; 102(18):6431-6. PubMed ID: 15843459
[TBL] [Abstract][Full Text] [Related]
9. Differential recognition of response elements determines target gene specificity for p53 and p63.
Osada M; Park HL; Nagakawa Y; Yamashita K; Fomenkov A; Kim MS; Wu G; Nomoto S; Trink B; Sidransky D
Mol Cell Biol; 2005 Jul; 25(14):6077-89. PubMed ID: 15988020
[TBL] [Abstract][Full Text] [Related]
10. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
[TBL] [Abstract][Full Text] [Related]
13. Predicting the transactivation activity of p53 missense mutants using a four-body potential score derived from Delaunay tessellations.
Mathe E; Olivier M; Kato S; Ishioka C; Vaisman I; Hainaut P
Hum Mutat; 2006 Feb; 27(2):163-72. PubMed ID: 16395672
[TBL] [Abstract][Full Text] [Related]
14. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
Müller P; Nenutil R; Vojtĕsek B
Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
[TBL] [Abstract][Full Text] [Related]
15. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity.
Gagnebin J; Kovar H; Kajava AV; Estreicher A; Jug G; Monnier P; Iggo R
Oncogene; 1998 Feb; 16(5):685-90. PubMed ID: 9482117
[TBL] [Abstract][Full Text] [Related]
16. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
Maurici D; Monti P; Campomenosi P; North S; Frebourg T; Fronza G; Hainaut P
Oncogene; 2001 Jun; 20(27):3533-40. PubMed ID: 11429700
[TBL] [Abstract][Full Text] [Related]
17. Tumour p53 mutations exhibit promoter selective dominance over wild type p53.
Monti P; Campomenosi P; Ciribilli Y; Iannone R; Inga A; Abbondandolo A; Resnick MA; Fronza G
Oncogene; 2002 Mar; 21(11):1641-8. PubMed ID: 11896595
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.
Kakudo Y; Shibata H; Otsuka K; Kato S; Ishioka C
Cancer Res; 2005 Mar; 65(6):2108-14. PubMed ID: 15781620
[TBL] [Abstract][Full Text] [Related]
19. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
20. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.
Fen CX; Coomber DW; Lane DP; Ghadessy FJ
J Mol Biol; 2007 Aug; 371(5):1238-48. PubMed ID: 17610896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]